Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia

Inclusion Criteria: * Willing and able to sign written informed consent prior to study entry. * Participants who self-identify as Asian; male or female, \>18 years of age. * Established diagnosis of type 2 diabetes (documented by either HbA1c 6.5 - 10.0% or a documented diagnosis of type 2 diabetes). * Treatment naïve or on active therapy with metformin at a daily dose of 500-3000 mg at screening. Dose of metformin must have been stable for at least 3 months prior to screening. * Participants must have a hematocrit value greater than or equal to 34.0% for females and 40% for males. * Participants must have a hemoglobin value greater than or equal to 11.0 g/dL for females and 13.5 g/dL for males. Exclusion Criteria: * Fasting plasma glucose \>220 mg/dl at screening. * Impaired kidney function, eGFR of \<60 mL/min/1.73 m2 at screening. * BMI \>35 kg/m2. * Weight ≤ 50 kg. * Elevated liver transaminase \> 3 ULN at screening. * Ongoing or recent (i.e. \< 3 month) treatment with any oral or injectable glucose-lowering drug other than metformin. * Ongoing or recent (i.e. \< 3 month) injectable insulin therapy. * Ongoing or recent (i.e. \< 3 month) weight loss interventions (e.g. dietary weight loss programs) or any history of bariatric surgery or any documented weight loss \>5% within previous 6 months. * Ongoing or recent (i.e. \< 3 month) treatment with anorectic drugs, systemic steroids, medications known to affect gastric motility, or any condition known to affect gastro-intestinal integrity and food absorption. * Major medical/surgical event requiring hospitalization in the last 3 months. * Known allergy and intolerance to product components or paracetamol. * Alcohol intake higher than 2 servings per day. A serving is 0.4 dl of strong alcohols, 1 dl of red or white wine, or 3 dl of beer. * Are unable to comply with protocol procedures in the opinion of the investigator. * Have a hierarchical link with the research team members. * Positive pregnancy test or breast-feeding at screening. * Participants who have been dosed in another clinical study with any investigational drug/new chemical entity within 30 days or 5 half-lives (whichever is longer) prior to screening. * Donation of blood or significant amount of blood loss within 8 weeks prior to screening. Participants must also agree to not donate blood within 8 weeks after their last visit.